US$30.9 million strategic equity deal strengthens Everest’s oncology platform
US$30.9 million strategic equity deal strengthens oncology platform US$30.9 million strategic equity deal strengthens oncology platform
Previous Post
Microbiotica completes recruitment for phase 1b ulcerative colitis trial
Next Post
Apolipoprotein B (ApoB) and the Real Risk of Heart Disease
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago